论文部分内容阅读
目的观察不同剂量非布司他对高尿酸血症患者炎性因子的影响。方法选取茂名市人民医院收治的高尿酸血症患者106例,采取数字随机表法分为大剂量组和小剂量组各53例,大剂量组给予非布司他80mg口服治疗,小剂量组给予非布司他40mg口服治疗,对比两组不同剂量非布司他治疗对炎性因子的影响。结果两组患者治疗后IL-6、TNF-α水平均低于治疗前,差异有统计学意义(P<0.05)。大剂量组患者治疗后IL-6、TNF-α水平均低于小剂量组,差异有统计学意义(P<0.05)。大剂量组用药不良反应发生率为3.77%高于小剂量组的1.89%,差异无统计学意义(P>0.05)。结论 80mg的非布司他更有利于患者炎性因子水平的改善,对高尿酸血症患者的治疗有利。
Objective To observe the effects of different doses of febuxostat on inflammatory cytokines in patients with hyperuricemia. Methods A total of 106 patients with hyperuricemia were enrolled in the People’s Hospital of Maoming. The patients were divided into high dose group and low dose group (n = 53) by random number table. The high dose group was given 80mg orally. The low dose group Non-Bupivarin 40mg oral treatment, comparing two groups of different doses of febuxostat treatment on the impact of inflammatory cytokines. Results After treatment, the levels of IL-6 and TNF-α in both groups were significantly lower than those before treatment (P <0.05). After treatment, the levels of IL-6 and TNF-α in the high-dose group were lower than those in the low-dose group, with significant difference (P <0.05). The incidence of adverse reactions in the high-dose group was 3.77% higher than that in the low-dose group (1.89%), the difference was not statistically significant (P> 0.05). Conclusion 80 mg of febuxostat is more conducive to the improvement of inflammatory cytokines in patients with hyperuricemia in the treatment of patients.